Inhalerx Ltd Asset Resilience Ratio
Inhalerx Ltd asset resilience ratio. Inhalerx Ltd (IRX) has an Asset Resilience Ratio of 46.96% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IRX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Inhalerx Ltd (2016–2022)
Asset resilience ratio of Inhalerx Ltd from 2016 to 2022. This chart shows how Inhalerx Ltd's Asset Resilience Ratio has changed over time. Read IRX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Inhalerx Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Inhalerx Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$525.99K | 46.96% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$525.99K | 46.96% |
Asset Resilience Insights
- Very High Liquidity: Inhalerx Ltd maintains exceptional liquid asset reserves at 46.96% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Inhalerx Ltd Industry Peers by Asset Resilience Ratio
Compare Inhalerx Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Inhalerx Ltd Asset Resilience Ratio by Year (2016–2022)
Inhalerx Ltd asset resilience ratio by year from 2016 to 2022. The table below shows the annual Asset Resilience Ratio data for Inhalerx Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 94.48% | AU$2.13 Million ≈ $1.51 Million |
AU$2.26 Million ≈ $1.60 Million |
-1.17pp |
| 2021-12-31 | 95.64% | AU$2.80 Million ≈ $1.98 Million |
AU$2.93 Million ≈ $2.07 Million |
+5.34pp |
| 2020-12-31 | 90.31% | AU$1.72 Million ≈ $1.22 Million |
AU$1.90 Million ≈ $1.35 Million |
+15.43pp |
| 2018-12-31 | 74.88% | AU$2.31 Million ≈ $1.64 Million |
AU$3.09 Million ≈ $2.19 Million |
-13.91pp |
| 2017-12-31 | 88.79% | AU$4.52 Million ≈ $3.20 Million |
AU$5.09 Million ≈ $3.60 Million |
+0.04pp |
| 2016-12-31 | 88.75% | AU$7.61 Million ≈ $5.38 Million |
AU$8.58 Million ≈ $6.07 Million |
-- |
About Inhalerx Ltd
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexali… Read more